Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vb-201. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | FABP3 | P05413 | 1/20 | 0.61 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.57 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.57 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | PTAFR | P25105 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
| ▸ | PRKCG | P05129 | 1/20 | 0.53 |
| ▸ | PRKCB | P05771 | 1/20 | 0.53 |
| ▸ | PRKCA | P17252 | 1/20 | 0.53 |
| ▸ | PRKCH | P24723 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | PRKCI | P41743 | 1/20 | 0.53 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15164286 | 1.00 | RECQL (0.64) | RECQLFABP3LPAR1LPAR3ADRA1D | |
| Vb-201 SCHEMBL15942776 | 1.00 | RECQL (0.64) | RECQLFABP3LPAR1LPAR3ADRA1D | |
| SCHEMBL8746968 | 1.00 | RECQL (0.64) | RECQLFABP3LPAR1LPAR3ADRA1D | |
| SCHEMBL12345691 | 1.00 | RECQL (0.64) | RECQLFABP3LPAR1LPAR3ADRA1D | |
| SCHEMBL19405591 | 0.92 | LPAR1 (0.67) | FABP3LPAR1LPAR3ADRA1DPTAFR | |
| SCHEMBL14447803 | 0.92 | LPAR1 (0.67) | FABP3LPAR1LPAR3ADRA1DPTAFR | |
| SCHEMBL22023008 | 0.92 | LPAR1 (0.67) | FABP3LPAR1LPAR3ADRA1DPTAFR | |
| SCHEMBL22023007 | 0.92 | LPAR1 (0.67) | FABP3LPAR1LPAR3ADRA1DPTAFR | |
| SCHEMBL20851913 | 0.92 | LPAR1 (0.67) | FABP3LPAR1LPAR3ADRA1DPTAFR | |
| SCHEMBL31282060 | 0.92 | LPAR1 (0.67) | FABP3LPAR1LPAR3ADRA1DPTAFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3223824-B1 | OXIDIZED LIPIDS AND TREATMENT OR PREVENTION OF FIBROSIS | VASCULAR BIOGENICS LTD (IL) | 2021-01-06 | — | — | EP | disclosed |
| US-10206936-B2 | Oxidized lipids and treatment or prevention of fibrosis | VASCULAR BIOGENICS LTD. (IL) | 2019-02-19 | — | — | US | disclosed |
| US-20180325928-A1 | Oxidized Lipids and Treatment or Prevention of Fibrosis | VASCULAR BIOGENICS LTD. (IL) | 2018-11-15 | — | — | US | disclosed |
| US-10022388-B2 | Oxidized lipids and treatment or prevention of fibrosis | VASCULAR BIOGENICS LTD. (UA) | 2018-07-17 | — | — | US | disclosed |
| US-20170258818-A1 | Oxidized Lipids and Treatment or Prevention of Fibrosis | VASCULAR BIOGENICS LTD. (IL) | 2017-09-14 | — | — | US | disclosed |
| CN-102834011-B | Use the treatment of 1-cetyl-2-(4 '-carboxybutyl)-glycerol-3-phosphocholine | VASCULAR BIOGENICS LTD. (IL) | 2016-01-13 | — | — | CN | disclosed |
| CN-104066706-A | Treatment of inflammation | VASCULAR BIOGENICS LTD | 2014-09-24 | — | — | CN | disclosed |
| CN-103874485-A | Formulations and dosage forms of oxidized phospholipids | VASCULAR BIOGENICS LTD | 2014-06-18 | — | — | CN | disclosed |
| CN-102834011-A | Treatment with VB-201 | VASCULAR BIOGENICS LTD | 2012-12-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10022388-B2 | Oxidized lipids and treatment or prevention of fibrosis | CPT1A, GPX4, LIPC | RECQL 2360/4885FABP3 64/4885LPAR1 388/4885 |
| US-20170258818-A1 | Oxidized Lipids and Treatment or Prevention of Fibrosis | CPT1A, GPX4, LIPC | RECQL 2360/4885FABP3 64/4885LPAR1 388/4885 |
| US-20180325928-A1 | Oxidized Lipids and Treatment or Prevention of Fibrosis | CPT1A, GPX4, LIPC | RECQL 2360/4885FABP3 64/4885LPAR1 388/4885 |
| US-10206936-B2 | Oxidized lipids and treatment or prevention of fibrosis | CPT1A, GPX4, LIPC | RECQL 2360/4885FABP3 64/4885LPAR1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.